Axovant Sciences Priced, NYSE: AXON

Newly formed biotech developing a late-stage Alzheimer's therapy acquired from GSK.

Industry: Health Care

Latest Trade: $5.65 0.00 (0.0%)

First Day Return: +99.3%

Return from IPO: -62.3%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. We are a wholly-owned subsidiary of Roivant Sciences, a company focused on the acquisition, development and commercialization of late-stage product candidates that are non-strategic, deprioritized or under-resourced at other biopharmaceutical companies. Our near-term focus is to develop RVT-101 for the treatment of Alzheimer's disease and other forms of dementia. We acquired the worldwide rights to RVT-101 from GlaxoSmithKline in December 2014. We plan to commence a Phase 3 pivotal program of RVT-101 for the treatment of mild-to-moderate Alzheimer's disease in the fourth quarter of 2015. Should our Phase 3 program be successful, we plan to rapidly seek regulatory approval and commercialization of RVT-101 in the United States and the European Union. In the long-term, we intend to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia.
more less
IPO News for Axovant Sciences
more
IPO Data
IPO File Date 05/11/2015
Offer Price $15.00
Price Range $13.00 - $15.00
Offer Shares (mm) 21.0
Deal Size ($mm) $315
IPO Data
IPO Date 06/10/2015
Offer Price $15.00
Price Range $13.00 - $15.00
Offer Shares (mm) 21.0
Deal Size ($mm) $315
Underwriters
more
Company Data
Headquarters Hamilton, Bermuda
Founded 2014
Employees 8
Website www.axovant.com